WESTFORD, Mass., Oct. 25, 2011 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO) today announced financial results for the three months ended September 30, 2011.
Financial Results
Third-quarter 2011 revenues increased 48 percent to $28.3 million from $19.1 million for the same period in 2010. The net loss for the quarter was $0.8 million, or $0.06 per basic and diluted share, which includes $0.4 million of expenses associated with the Company’s June acquisition of the aesthetic laser assets of HOYA ConBio®. The Company broke even from operations on an adjusted basis, excluding the acquisition expenses, compared with an operating loss of $1.0 million for the third quarter of 2010. The improvement in operating performance reflects increased revenues and improved operating expense leverage.
“We generated our highest quarterly revenue since 2008, which reflected the combination of key asset acquisitions and our strongest organic growth in North America in three years,” said Michael Davin, Cynosure’s President and Chief Executive Officer. “Internationally, laser product revenue grew 60 percent from the third quarter of 2010. This result was attributable primarily to the effect of our ConBio and SmoothShapes XV acquisitions, which complement our geographic reach and product offerings. In North America, third-quarter laser product revenue grew 16 percent organically and 54 percent overall. While the acquisitions contributed to the overall increase, we also benefitted from solid gains in our core business, due largely to improvements in the North American lending environment. While credit availability is still far from pre-recession levels, our ongoing efforts to bring together creditworthy aesthetic practitioners and financial institutions yielded positive results in the quarter.”
Gross profit for the three months ended September 30, 2011 was 56.5 percent, compared with 56.1 percent for the same period of 2010. The improvement in gross margin reflects slightly higher average selling prices as well as favorable geographic and product mix.
Total operating expenses for the third quarter of 2011 were $16.4 million, or 58 percent of revenues, including $0.4 million of expenses associated with the acquisition of ConBio. Operating expenses totaled $11.7 million, or 61 percent of revenues, for the third quarter of 2010.
Recent Highlights
- Cynosure announced that it has acquired worldwide exclusive rights to distribute the PinPointe FootLaser, the world’s first FDA cleared light-based device for the treatment of Onychomycosis (toenail fungus), a condition that affects approximately 36 million people in the United States and an estimated 10 percent of the population worldwide.
- Cynosure is continuing the European rollout of its Cellulaze workstation, the world’s first minimally invasive aesthetic laser for long-lasting reduction of cellulite in a single treatment. The Company recorded initial Cellulaze sales in the third quarter, and is in the process of introducing the product in Australia and Canada. The Company’s 510(k) application for marketing clearance of Cellulaze in the United States is continuing to undergo review by the U.S. Food and Drug Administration.
- During the third quarter of 2011, the Company began shipments of the ‘Petite’ laser handpiece for the newly acquired SmoothShapes XV system. The Petite handpiece is 50 percent lighter than the first-generation device. The system delivers a 50 percent increase in power density over the prior generation, allowing practitioners enhanced flexibility to treat smaller cosmetic areas such as the arms, neck and calves.
“In conjunction with our new minimally invasive Cellulaze technology, SmoothShapes XV reflects our strategy to provide aesthetic practitioners and their patients with a turnkey solution for cellulite reduction,” Davin said. “Response to SmoothShapes XV’s new Petite handpiece has been extremely positive. The workstation is being sold in North America, South America and Europe, and we expect the product to continue to gain traction in the quarters ahead.”
Business Outlook
“We enter the final quarter of 2011 in a strong position both operationally and financially,” Davin said. “Revenue through the first nine months of 2011 is 29 percent ahead of our pace in 2010. Our newly acquired aesthetic laser products are performing well and we have been pleased to see the favorable impact our direct distribution is having on communicating the value of these newly acquired products to the marketplace. We have begun to realize some initial synergies from our acquisition of ConBio, and we expect additional synergies and cost savings from the transaction as we complete the integration process.”
“On the development front, we remain pleased with the progress of our joint agreement with Unilever to create a laser treatment system for the home use personal care market. Product commercialization remains on track for 2012,” Davin said. “Additionally, we are on schedule to launch our next flagship product for a new aesthetic indication during the latter half of next year. Our balance sheet remains healthy, with $66 million in cash and securities and no long-term debt, and we continue to explore potential acquisition opportunities.”
Third-Quarter Financial Results Conference Call
In conjunction with its third-quarter 2011 financial results, Cynosure will host a conference call for investors and analysts at 9:00 a.m. ET today. On the call, Michael Davin and Timothy Baker, the Company’s Executive Vice President and Chief Financial Officer, will discuss Cynosure’s financial results and provide a business overview. Those who wish to listen to the conference call webcast should visit the “Investor Relations” section of the Company’s website at www.cynosure.com. The live call can also be accessed by dialing (877) 407-5790 or (201) 689-8328. If you are unable to listen to the live call, the webcast will be archived on the Company’s website.
About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis, reduce the appearance of cellulite and treat Onychomycosis. Cynosure’s products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Q-switched, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the Company’s anticipated financial results, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the global economy and lending environment and their effects on the aesthetic laser industry, Cynosure’s history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure’s most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure’s views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure’s views as of any date subsequent to the date of this press release.
